National Health Act 1953 - Determinations under sections 93 and 93aa - Pharmaceutical benefits supplied by medical practitioners and authorised nurse practitioners (No. PB 103 of 2010) (Cth)

PB 103 of 2010

Determinations — Pharmaceutical benefits supplied by medical practitioners and authorised nurse practitioners

as amended

made under sections 93 and 93AA of the

National Health Act 1953

This compilation was prepared on 1 September 2012
taking into account amendments up to PB 62 of 2012

Prepared by the Office of Legislative Drafting and Publishing,
Attorney‑General’s Department, Canberra

Determinations — Pharmaceutical benefits supplied by medical practitioners and authorised nurse practitioners

1.      Name of Instrument [see Note 1]

(a)     The name of this Instrument is Determinations under sections 93 and 93AA of the National Health Act 1953.

(b)     This Instrument may also be cited as “No. PB 103 of 2010”.

2.      Commencement

This Instrument commences on 1 November 2010.

3.      Repeal

Determination No. PB 57 of 2007 under section 93 of the National Health Act 1953, made on 24 July 2007 with effect from 1 August 2007 (as amended) is repealed.

4.      Definitions

In this Instrument:

“Act” means the National Health Act 1953;

“authorised nurse practitioner” has the meaning given by subsection 84(1) of the Act.

5.      Pharmaceutical benefits

A pharmaceutical benefit which has a listed drug in a form mentioned in the Schedule is a pharmaceutical benefit which a medical practitioner and an authorised nurse practitioner is authorised to supply.

6.      Maximum quantity or number of units

The maximum quantity or number of units of a pharmaceutical benefit which may be obtained by a medical practitioner or authorised nurse practitioner in any period of one month is the quantity or number of units mentioned in the Schedule under the column “maximum quantity” for the listed drug in the form mentioned less the quantity or number of units of the pharmaceutical benefit previously obtained in accordance with sections 93 and 93AA of the Act and still in the possession of the medical practitioner or authorised nurse practitioner.

THE SCHEDULE
Pharmaceutical benefits for supply by medical practitioners and authorised nurse practitioners
Listed Drug		Form (strength, type, size, etc.)		Maximum quantity
Adrenaline		Injection 1 mg (as acid tartrate) in 1 mL (1 in 1,000)		5
Atropine		Injection containing atropine sulfate 600 micrograms in 1 mL		10
Benztropine		Injection containing benztropine mesylate 2 mg in 2 mL		5
Benzylpenicillin		Powder for injection 600 mg (as sodium)		10
OR
Procaine Penicillin		Injection 1.5 g in disposable syringe		5
Benzylpenicillin		Powder for injection 3 g (as sodium)		1
Chlorpromazine		Injection containing chlorpromazine hydrochloride 50 mg in 2 mL		10
OR
Haloperidol		Injection 5 mg in 1 mL		10
Clonazepam		Oral liquid 2.5 mg per mL, 10 mL		1
Dexamethasone		Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL		5
OR
Hydrocortisone		Injection 100 mg (as sodium succinate) with 2 mL solvent		2
OR
Hydrocortisone		Injection 250 mg (as sodium succinate) with 2 mL solvent		1
Diazepam		Injection 10 mg in 2 mL		5
Diphtheria and tetanus vaccine, adsorbed, diluted for adult use		Injection 0.5 mL in pre-filled syringe		20
Frusemide		Injection 20 mg in 2 mL		5
Glucagon		Injection set containing glucagon hydrochloride 1 mg (1 I.U.) and 1 mL solvent in disposable syringe		1
Glyceryl Trinitrate		Sublingual spray (pump pack) 400 micrograms per dose, 200 doses		1
Hyoscine		Injection containing hyoscine butylbromide 20 mg in 1 mL		5
Lignocaine		Injection containing lignocaine hydrochloride 100 mg in 5 mL		5
Metoclopramide		Injection containing metoclopramide hydrochloride 10 mg in 2 mL		10
OR
Prochlorperazine		Injection containing prochlorperazine mesylate 12.5 mg in 1 mL		10
Morphine		Injection containing morphine sulfate 15 mg in 1 mL		5
OR
Morphine		Injection containing morphine sulfate 30 mg in 1 mL		5
Naloxone		Injection containing naloxone hydrochloride 2 mg in 5 mL disposable injection set		2
Promethazine		Injection containing promethazine hydrochloride 50 mg in 2 mL		10
Salbutamol		Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation)		1
OR
Salbutamol		Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30		1
Salbutamol		Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30		1
Terbutaline		Injection containing terbutaline sulfate 500 micrograms in 1mL		5
Tramadol		Injection containing tramadol hydrochloride 100 mg in 2 mL		5
Verapamil		Injection containing verapamil hydrochloride 5 mg in 2 mL		5

Notes to the Determinations — Pharmaceutical benefits supplied by medical practitioners and authorised nurse practitioners (PB 103 of 2010)

Note 1

The Determinations — Pharmaceutical benefits supplied by medical practitioners and authorised nurse practitioners (PB 103 of 2010) (in force under subsections 93 and 93AA of the National Health Act 1953) as shown in this compilation is amended as indicated in the Tables below.

Table of Instruments

Title	Date of FRLI registration	Date of commencement	Application, saving or transitional provisions
PB 103 of 2010	29 Oct 2010 (see F2010L02861)	1 Nov 2010
PB 110 of 2010	30 Nov 2010 (see F2010L03135)	1 Dec 2010	—
PB 32 of 2011	13 Apr 2011 (see F2011L00606)	1 May 2011	—
PB 62 of 2012	15 Aug 2012 (see F2012L01681)	1 Sept 2012	—

Table of Amendments

ad. = added or inserted      am. = amended      rep. = repealed      rs. = repealed and substituted
Provision affected	How affected
Schedule
Schedule..................................	am. PB 110 of 2010; PB 32 of 2011; PB 62 of 2012